Vaccinex Announces Delisting Decision from Nasdaq
Vaccinex Inc. (OTC: VCNX), a clinical-stage biotechnology company dedicated to treating neurodegenerative diseases, has announced plans to delist its common stock from the Nasdaq Stock Market.
This decision follows a significant notice from Nasdaq's Hearings Panel, which determined the need for the company's securities to be removed from listing. Following the suspension of trading on December 18, 2024, Vaccinex aims to submit a Form 25 with the Securities and Exchange Commission shortly, expected around mid-March, initiating the official delisting process.
Reasons Behind the Delisting Move
The impetus for the company's actions stems from market dynamics and strategic evaluations of its operational focus. With trading activity suspended for months, Vaccinex has taken this decisive step to align its resources and efforts with its core mission.
The company remains committed to advancing the development of its lead product, pepinemab, which targets Alzheimer's disease and various cancers.
Continued Focus on Product Development
Despite the delisting, Vaccinex is steadfast in its mission to innovate therapeutic solutions. Pepinemab leverages a unique mechanism of action by inhibiting SEMA4D, aimed at curtailing neuroinflammation and astrocytic activation associated with neurodegenerative diseases. This strategic focus signifies the company’s commitment to breakthrough treatments while exploring various funding avenues.
Current Clinical Programs
Pepinemab is undergoing extensive clinical evaluation as a monotherapy in Alzheimer's disease through the Phase 1b/2 SIGNAL-AD study, exhibiting potential in both disrupting disease progression and serving as a vital component in combination therapies.
In oncology, it is under assessment in combination with renowned immune checkpoint inhibitors in the KEYNOTE-B84 study for recurrent head and neck cancer, alongside collaborative evaluations with other treatments for pancreatic cancer.
About Vaccinex Inc.
Vaccinex Inc. has distinguished itself in researching treatments for progressive neurodegenerative conditions and oncological disorders. Their innovative approaches harness the regulatory abilities of pepinemab, which is engineered to mitigate harmful inflammatory responses associated with brain disorders and bolster anti-tumor immune responses.
The firm maintains global rights for the commercialization and advancement of pepinemab, in collaboration with top-tier pharmaceutical entities.
The Future of Vaccinex and Pepinemab
The company remains optimistic about the potential for pepinemab to make significant impacts on patient outcomes in Alzheimer's and cancer treatment realms. Engaging with collaborators and securing grants to fuel research endeavors, Vaccinex looks to capitalize on its R&D capabilities.
Investor Relations
For inquiries, please contact Elizabeth Evans, PhD, Chief Operating Officer at Vaccinex, Inc. You can reach her at (585) 766-2033.
Frequently Asked Questions
What is Vaccinex planning regarding its Nasdaq listing?
Vaccinex has announced it will delist its common stock from Nasdaq in response to trading suspensions and strategic realignments.
What is pepinemab?
Pepinemab is an innovative monoclonal antibody being developed by Vaccinex to treat Alzheimer’s disease and certain cancers.
How has vaccinations' trading been affected?
Vaccinex's trading has been suspended since December 2024 due to Nasdaq's decision, leading to the proposed delisting.
What are Vaccinex's future plans?
The company intends to focus on developing pepinemab through partnerships and funding to advance its research programs.
Who can potential investors contact for more information?
Elizabeth Evans, PhD, the Chief Operating Officer, is available for inquiries and can be reached at (585) 766-2033.
